Pubblicazioni dal 1992 al 2000

 

1992

 

Cocconi G., Bisagni G., Ceci G., Bacchi M., Boni C., Brugia M., Carpi A., Di Costanzo F., Franciosi V., Gori S., Indelli M., Passalacqua R.

Low-dose aminogluthetimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research

Journal of  Clinical Oncology 10:984-989, 1992 (IF=17.793)

 

Di Costanzo F., Bartolucci R., Calabresi F., Sofra M., Marzola M., Belsanti V., Boni C., Bacchi M.

Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC).

Annals of Oncology, 3:371-376, 1992. (IF=5.647)

 

Cocconi G., Bella M., Calabresi F., Tonato M., Canaletti R., Boni C., Buzzi F., Ceci G., Corgna E., Costa P., Lottici R., Papadia F., Sofra M., Bacchi M.

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.

New England Journal of Medicine 327: 516-523, 1992. (IF=47.050)

 

Di Costanzo F.

Best treatment for colorectal cancer and confirmatory trials.

Annals of Oncology 3 (3): 245-246, 1992. (IF=5.647)

 

1994

 

Bisagni G., Cocconi G., Ceci G., De Lisi V., Di Blasio B., Lottici R., Passalacqua R., Finardi C.

M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma. A phase II study.

Annals of Oncology, 5: 93-94, 1994. (IF=5.647)

 

Cocconi G., Bella M., Zironi S., Algeri R., Di Costanzo F., De Lisi V., Luppi G., Mazzocchi B., Rodinò C., Soldani M., Gilli G., Finardi C.

Fluorouracil, Doxorubicin, and Mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research.

Journal of  Clinical Oncology 12: 2687-2693, 1994. (IF=17.793)

 

Cocconi G, Bisagni G, Ceci G, Bacchi M:

Aminoglutethimide: the problem of the optimal dose and the indispensability or not of hydrocortisone.

In "Clinical use of aromatase inhibitors. Current data and future prospective",

1. Robustelli Della Cuna, A. Manni, F. Pannuti, EDIMES Ed., Pavia, pp. 97-105, 1994

 

1995

 

Ceci G., Bisagni G., Cocconi G., Rodinò C., Belsanti V., Bertusi M., Buzzi F., Bacchi M.:

Cisplatin and VP16 in metastatic breast carcinoma as a third line chemotherapy. A randomized study comparing low vs high doses of Cisplatin.

Tumori 81: 241-244, 1995

                                       

Crinò L., Clerici M., Figoli F., Carlini P., Ceci G., Cortesi E., Carpi A., Santini A., Di Costanzo F., Boni C., Meacci M., Corgna E., Darwish S., Scarcella L., Santucci A., Ballatori E., Tonato M.

Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)

Annals of Oncology 6: 347-353, 1995. (IF=5.647)

 

Crinò L., Clerici M., Figoli F., Barduagni M., Carlini P., Ceci G., Cortesi E., Carpi A., Santini A., Di Costanzo F. et al.

Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell ling cancer: a randomized trial by the Italian Oncology Group for Clinical Research.

Lung Cancer 12 (suppl 1): S125-132, 1995.

 

1996

 

De Lisi V., Cocconi G., Angelini F., Cavicchi F., Di Costanzo F., Gilli G., Rodinò C., Soldani M., Tonato M., Finardi C.

The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma.

Cancer 77: 245-250, 1996.

 

Di Costanzo F., Tagliaventi M., Carlini P., Zironi S., Mazzocchi B., Bella M., Donati D., Acito L., Maggian P., Angiona S.

High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (GOIRC).

American Journal of Clinical Oncology 19 (3): 307-310, 1996.

 

Di Costanzo F., Gasperoni S., Labianca R., Sdrobolini A., Zamparelli G., Angiona S., Bartolucci R., Rossetti R. on behalf of GOIRC and GISCAD.

Preliminary report of an ongoing trial comparing surgery alone versus surgery and chemotherapy in operable gastric cancer.

Journal of Chemotherapy 8 suppl. 4: 104-106, 1996.

 

1997

 

Passalacqua R., Cocconi G., Caminiti C., Silingardi V., Bella M.A., Bichisao E., Michiara M., Malavasi V., Donati D., Di Costanzo F., Rocca A., Di Sarra S., Scaglione F., Fraschini F.

Double-blind , multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients.

Journal of Clinical Oncology 15: 2467-2473, 1997. (IF=17.793)

 

1998

 

Di Costanzo F., Gasperoni S., Malacarne P., Belsanti V., Luppi G., Marzola M., Corgna E., Sdrobolini A., Passalacqua R., Figoli F., Algeri R., Zironi S., Angiona S., Boni C.

High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.

American Journal of Clinical Oncology 21 (4): 369-375, 1998.

 

Boni C., Savoldi L., Bisagni G., Ceci G., Crinò L., De Lisi V., Di Costanzo F., Lasagni L., Manenti AL., Moretti G., Rondini E., Sassi M., Zadro A.

Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC).

European Journal of Cancer 34 (12): 1974-1976, 1998. (IF=4.121)

 

1999

 

Franciosi V., Cocconi G., Michiara M., Di Costanzo F., Fosser V., Tonato M., Carlini P., Boni C., Di Sarra S.

Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non small cell lung carcinoma, or malignant melanoma.

Cancer 85: 1599-1605, 1999

 

Cocconi G., Bisagni G., Ceci G., Di Blasio B., De Lisi V., Passalacqua R., Zadro A., Boni C., Morandi P., Savoldi L.:

Three new highly active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma. A randomized phase II trial.

Breast Cancer Res. Treat.56: 125-132, 1999. IF=4.696)

 

Cocconi G., Bella M.A., Lottici R., Leonardi F., Ceci G., Passalacqua R., Di Blasio B., Bordi C., Biscottini B., Melpignano M., De Biasi D., Finardi C., Bacchi M.:

Mature results of a prospective randomized trial comparing two different time schedule of cisplatin in advanced ovarian carcinoma.

American Journal of Clinical Oncology 22: 559-567, 1999. (IF=2.206)

 

Cocconi G., Bisagni G., Bella M., Acito L., Anastasi P., Carpi A., Di Costanzo F., Frassoldati A., Mosconi A., Borrini A., Buzzi P.

Comparison of CMF (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer. A prospective randomized trial.

American Journal of Clinical Oncology 22: 593-600, 1999. (IF=2.206)

 

2000

 

Boni C., Bisagni G., Savoldi L., Moretti G., Rondini E., Sassi M., Zadro A., De Pas T., Franciosi V., Pazzola A., Vignoli R., Banzi M.C., Pajetta V.

Gemcitabine, Ifosfamide, Cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).

International Journal of Cancer 87: 724-727, 2000. (IF=4.722)

 

Di Costanzo F., Canaletti R., Sdrobolini A., Olmeo N., Luppi G., Pucci F., Cavicchi F., Gasperoni S.,

Rodinò C., Zironi S., Angiona S., Contu A.

Modulation of fluorouracil by methotrexate, leucovorin and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).

American Journal of Clinical Oncology 23 (3): 314-318, 2000. (IF=2.206)